Holly E Pariury

Interests

Research

- Leukemia - Lymphoma- Targeted therapies- Supportive Care

Teaching

- Medical education for medical students and residents in hematology, oncology, critical illness, delivery of difficult news to families, supportive care, and palliative care - Curriculum development

Courses

Scholarly Contributions

Journals/Publications

• Pariury, H., Fandel, J., Bachl, S., Ang, K., Markossian, S., Wilson, C., Wohlfeil, M., Xirenayi, S., Beckman, K., Roy, R., Olshen, A., Arkin, M., Loh, M., & Diaz-Flores, E. (2023). Venetoclax and Dinaciclib demonstrate synergistic anti-leukemic efficacy against hypodiploid acute lymphoblastic leukemia in preclinical studies. Haematologica, 108(5), 12.
• Truscott, L., Pariury, H., Hanmod, S., Davini, M., de la Maza, M., Sapp, L. N., Staples, K., Proytcheva, M., & Katsanis, E. (2023). Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Pediatric blood & cancer, 70(2), e30102.
  More info

  Allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for patients with high-risk myeloid malignancies.
• Memmott, T., Alfonso, J. H., Udayasankar, U., & Pariury, H. (2022). Combination therapy for unresectable primitive myxoid mesenchymal tumor of infancy: A story of cure. Pediatric blood & cancer, 69(7), e29523.
• Memmott, T., Hass Alfonso, J., Udayasankar, U., & Pariury, H. (2021). Combination Therapy for Unresectable Primitive Myxoid Mesenchymal Tumor of Infancy: A Story of Cure. Manuscript, e29523, 2.
• Pariury, H. (2021). Re-emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia. Frontiers in Oncology.
• Pariury, H., Truscott, L., & Katsanis, E. (2021). Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?. Oncoimmunology, 10(1), 1956125.
  More info

  The treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has undergone several recent advancements, leading to an increased amount of treatment options for relapsed patients. The development of immunotherapies such as anti-CD19 chimeric antigen receptor(CAR) T cells and bispecific T-cell engagers has given clinicians therapeutic options with less expected toxicity when compared to standard re-induction chemotherapy. This is especially beneficial in patients with toxicities from their prior treatment. Along with this, the emergence of haploidentical hematopoietic cell transplantation (HCT) has increased opportunity for patients to receive HCT who may not have had an available matched donor. We present four patients who have received all of these therapies in different combinations to treat multiple relapses. Because of the success of achieving remission as well as decreasing toxicity, the patients are alive and well up to 15 y after the original B-ALL diagnosis, rendering this as a chronic disease for them.
• Kay, M. D., Pariury, H. E., Perry, A., Winegar, B. A., & Kuo, P. H. (2019). Extracranial Metastases From Glioblastoma With Primitive Neuronal Components on FDG PET/CT. Clinical nuclear medicine.
  More info

  A 17-year-old girl with World Health Organization grade IV glioblastoma with primitive neuronal components (histone H3 G34-mutant and IDH1 wild type) underwent whole-body FDG PET/CT staging due to vertebral metastases on initial MRI. PET/CT revealed extracranial metastatic disease with spinal leptomeningeal dissemination, osseous metastases, and peritoneal seeding via a ventriculoperitoneal shunt. Glioblastoma is uncommon in pediatric patients and particularly those with primitive neuronal components. Extracranial metastases from glioblastoma are more common in those with primitive neuronal components. This case demonstrates the utility of FDG PET/CT for revealing distant metastases from glioblastoma.
• Pariury, H., Golden, C., Huh, W. W., Cham, E., Chung, T., & Hayes-Jordan, A. (2019). Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy. Pediatric blood & cancer, 66(7), e27753.
  More info

  Ovarian angiosarcoma is a rare and aggressive vascular tumor, which has a 5-year overall survival of less than 30% for patients with nonmetastatic disease and almost certain death within 1 year for those with metastasis. Here, we briefly review historical approaches to therapy and present a long-term survivor in the case of an 11-year-old female with metastatic ovarian angiosarcoma. This is the second reported case to utilize heated intraperitoneal chemotherapy in the treatment of this disease. Our patient is currently alive and well 3 years after initial diagnosis, significantly longer than any reported case of advanced-stage ovarian angiosarcoma.
• Pariury, H., Willhoite, J., Michlitsch, J., & Agrawal, A. (2019). Potassium supplementation mitigates corticosteroid-induced neuropsychiatric effects in pediatric oncology patients. Pediatric hematology and oncology, 36(7), 445-450.
  More info

  Corticosteroids play an essential role in the treatment of pediatric malignancies, but have many untoward side effects including behavioral and mood disturbances which can be quite burdensome to families. Potassium chloride has been used anecdotally to decrease these neuropsychiatric effects but this experience has not been studied systematically. We therefore retrospectively reviewed our experience utilizing KCl supplementation to reduce corticosteroid-induced neuropsychiatric effects among children with acute lymphoblastic leukemia. Thirteen of 16 patients (81%) had a objective benefit with KCl at a median dose of 0.5 mEq/kg/day, with no reported adverse effects. Further prospective study is required to confirm these data.

Presentations

• Pariury, H. (2021, Spring). Changing the outcomes of pediatric leukemia; Immunotherapy in relapsed ALL. Grand Rounds. University of Arizona Cancer Center.
• Pariury, H. (2020, April). Management of Relapsed Acute Lymphoblastic Leukemia. Multi-institutional divison meeting.

Poster Presentations

• Shah, M., Goeken, B., Seckeler, M., Pariury, H., & Hoyer, A. (2022, October). Evaluation of change in QTc interval in children and young adults with cancer. First International Pediatric Cardio-Oncology Conference. Cincinnati, OH.